|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Platelet Reactivity
Test CodeP2Y12
Alias/See Also
VerifyNow
Plavix Resistance
P2Y12
LAB0000462
Plavix Resistance
P2Y12
LAB0000462
Preferred Specimen
2 blue Greiner tubes
Minimum Volume
Must be full draw
Instructions
May only be collected at Downtown Lab Testing or at Lancaster General Hospital.
Must be transported immediately by hand. May NOT use the Pevco tube system.
Must be transported immediately by hand. May NOT use the Pevco tube system.
Specimen Stability
2 hours, room temperature
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Specimen NOT hand delivered, wrong tube, short draw tube
Reference Range
A reference range study was conducted in 152 healthy donors by performing platelet function testing using VerifyNow PRUTest. The reference range determined from this study, expressed as the central 95% confidence interval of the mean, is 182–335 PRU.
PRU was measured in two groups of ACS patients: 1) 84 patients that were not receiving a P2Y12 receptor inhibiting drug, and 2) 71 patients with ACS receiving dual treatment with aspirin (ASA) and clopidogrel.
Clopidogrel
No Yes
N 84 71
Mean ± SD 274 ±48 156 ± 73
Lower and upper ranges (95% Cl)
Lower 180 (160-200) 6 (0-34)
Upper 376 (358-395) 300 (269-329)
Patients who have been treated with Glycoprotein llb/llla inhibitor drugs should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of drug administration for abciximab (ReoPro) and up to 48 hours for eptifibatide (Integrilin) and tirofiban (Aggrastat). Results should be interpreted in conjunction with other clinical and laboratory data available to the clinician.
PRU was measured in two groups of ACS patients: 1) 84 patients that were not receiving a P2Y12 receptor inhibiting drug, and 2) 71 patients with ACS receiving dual treatment with aspirin (ASA) and clopidogrel.
Clopidogrel
No Yes
N 84 71
Mean ± SD 274 ±48 156 ± 73
Lower and upper ranges (95% Cl)
Lower 180 (160-200) 6 (0-34)
Upper 376 (358-395) 300 (269-329)
Patients who have been treated with Glycoprotein llb/llla inhibitor drugs should not be tested until platelet function has recovered. This time period is approximately 14 days after discontinuation of drug administration for abciximab (ReoPro) and up to 48 hours for eptifibatide (Integrilin) and tirofiban (Aggrastat). Results should be interpreted in conjunction with other clinical and laboratory data available to the clinician.
Performing Laboratory
Penn Medicine Lancaster General Hospital
